None
Quote | Taiwan Liposome Company Ltd. (NASDAQ:TLC)
Last: | $7 |
---|---|
Change Percent: | 0.0% |
Open: | $7 |
Close: | $7 |
High: | $7 |
Low: | $7 |
Volume: | 8,606 |
Last Trade Date Time: | 09/28/2021 11:27:03 am |
News | Taiwan Liposome Company Ltd. (NASDAQ:TLC)
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Sele...
Message Board Posts | Taiwan Liposome Company Ltd. (NASDAQ:TLC)
Subject | By | Source | When |
---|---|---|---|
#DDAmanda Chart on: $TLC | TraderStig | investorshub | 09/23/2021 1:27:29 AM |
$TLC READY $FOR SOME NEWS . | FROZENFLAME | investorshub | 11/16/2020 12:19:32 AM |
$$$TLC$$$ | FROZENFLAME | investorshub | 11/06/2020 5:35:11 PM |
https://ir.tlcbio.com/news-releases/news-release-details/tlc-announces-acceptanc | FROZENFLAME | investorshub | 11/03/2020 7:28:59 PM |
Nice close . | FROZENFLAME | investorshub | 11/02/2020 10:09:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Taiwan Liposome Company Ltd. Company Name:
TLC Stock Symbol:
NASDAQ Market:
Taiwan Liposome Company Ltd. Website:
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Sele...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreem...